For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 33,719 | |||
| General and administrative | 9,252 | |||
| Total operating expenses | 42,971 | |||
| Loss from operations | -42,971 | |||
| Interest income and other expense, net | 2,505 | |||
| Change in fair value of warrant liability | -27,141 | |||
| Loss before equity method investment | -13,325 | |||
| Loss from equity method investment | -1,958 | |||
| Net loss | -15,283 | |||
| Unrealized gain (loss) on marketable securities | -17 | |||
| Cumulative foreign currency translation adjustment | 409 | |||
| Comprehensive loss | -14,891 | |||
| Basic EPS | -0.19 | |||
| Diluted EPS | -0.53 | |||
| Basic Average Shares | 78,964,842 | |||
| Diluted Average Shares | 79,742,685 | |||
Corvus Pharmaceuticals, Inc. (CRVS)
Corvus Pharmaceuticals, Inc. (CRVS)